Y Intercept Hong Kong Ltd Has $58,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Y Intercept Hong Kong Ltd increased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 162.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,782 shares of the biotechnology company’s stock after acquiring an additional 24,635 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Ironwood Pharmaceuticals were worth $58,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $36,000. Simplicity Wealth LLC bought a new position in Ironwood Pharmaceuticals in the first quarter worth approximately $45,000. Envestnet Asset Management Inc. bought a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $50,000. Boothbay Fund Management LLC acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $57,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $59,000.

Ironwood Pharmaceuticals Trading Down 8.3%

Shares of NASDAQ:IRWD opened at $0.76 on Friday. The stock has a market cap of $123.63 million, a PE ratio of -3.82 and a beta of 0.30. The stock’s fifty day simple moving average is $0.71 and its two-hundred day simple moving average is $1.30. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $7.08.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. The firm had revenue of $41.14 million for the quarter, compared to the consensus estimate of $67.02 million. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IRWD. Leerink Partners cut their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating on the stock in a report on Monday, April 14th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. Citizens Jmp downgraded shares of Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 14th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.78.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.